Extended Data Fig. 4: Lz-TRAIL-mediated senolysis in additional alisertib induced senescent cell models.
From: cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
a, Incucyte cell proliferation assay showing 0.5 µM alisertib-induced senescent A549 cells were treated with 100 ng/ml Lz-TRAIL. b, Senescence-associated with beta-galactosidase staining in A549 parental and alisertib-induced senescent cells treated with 200 ng/ml Lz-TRAIL. c, Senescence-associated with beta-galactosidase staining in a panel of cell lines treated with alisertib. The black scale bars present 100 µm. d, Dose-response curves of alisertib-induced senescent and proliferating CDKN2A mutant cell models upon Lz-TRAIL treatment (the result represents at least 3 repeats with similar results). e, Cell viability-based colony formation assay with alisertib-induced senescent and proliferating CDKN2A wild-type cell models upon 100 ng/ml Lz-TRAIL treatment. Error bars in this figure panel a-c, e represent as mean ± standard deviations, N = 3 independent experiments, statistical significance was calculated by two-tailed t-test.
